[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.176.107. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Correspondence
December 2001

A Prospective Open Study of Topical Psoralen–UV-A Therapy for Necrobiosis Lipoidica

Arch Dermatol. 2001;137(12):1658-1660. doi:

Necrobiosis lipoidica (NL) affects 0.3% of patients with diabetes mellitus.1 It can occur in patients without diabetes mellitus, 42% of whom have an impaired glucose tolerance test result (54% of whom have a strong family history of diabetes). Of patients with NL, 84% have more than 1 plaque, and 50% have more than 4. Plaques can be associated with paraesthesia, pruritus, or pain and can be disabling when associated with ulceration.2 There is no satisfactory treatment for NL.

First Page Preview View Large
First page PDF preview
First page PDF preview
×